New hope for rare gut cancer: drug showdown after standard therapy fails
NCT ID NCT04633122
First seen Apr 06, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study tested a new drug called ripretinib against an older drug, sunitinib, in 108 people with advanced gastrointestinal stromal tumors (GIST) whose cancer had stopped responding to the first-line treatment imatinib. The goal was to see which drug better delays cancer growth. Participants were randomly assigned to receive either ripretinib or sunitinib. The study was completed in China and focused on measuring how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China
-
Fudan University, Zhongshan Hospital
Shanghai, Shanghai Municipality, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The 4th Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
The Affiliated Hospital of Haerbin MedicalUniversity
Harbin, Heilongjiang, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
-
The Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
-
The Cancer Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Chongqing Medical Universty
Chongqing, Chognqing, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
The General Hospital of Peking University
Beijing, Beijing Municipality, China
-
The sixth Affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
Union Hospital of HUST
Wuhan, Hubei, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.